University of Hertfordshire

By the same authors

Standard

An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. / O'reilly, Aine; Hughes, Peta; Mann, Jasmine; lai, Zhuangming; Jiat Teh, Jiah; Edmonds, Kim; Lingard, Karla; Chauhan, Dharmisha; Lynch, Joanna; Au, Lewis; Ludlow, Aileen; Pattison, Natalie; Wiseman, Theresa; Turajic, Samra; Gore, Martin; Larkin, James; Husson, Olga.

In: Supportive Care in Cancer, 14.05.2019, p. 10.

Research output: Contribution to journalArticlepeer-review

Harvard

O'reilly, A, Hughes, P, Mann, J, lai, Z, Jiat Teh, J, Edmonds, K, Lingard, K, Chauhan, D, Lynch, J, Au, L, Ludlow, A, Pattison, N, Wiseman, T, Turajic, S, Gore, M, Larkin, J & Husson, O 2019, 'An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors', Supportive Care in Cancer, pp. 10. https://doi.org/10.1007/s00520-019-04818-w

APA

O'reilly, A., Hughes, P., Mann, J., lai, Z., Jiat Teh, J., Edmonds, K., Lingard, K., Chauhan, D., Lynch, J., Au, L., Ludlow, A., Pattison, N., Wiseman, T., Turajic, S., Gore, M., Larkin, J., & Husson, O. (2019). An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. Supportive Care in Cancer, 10. https://doi.org/10.1007/s00520-019-04818-w

Vancouver

Author

O'reilly, Aine ; Hughes, Peta ; Mann, Jasmine ; lai, Zhuangming ; Jiat Teh, Jiah ; Edmonds, Kim ; Lingard, Karla ; Chauhan, Dharmisha ; Lynch, Joanna ; Au, Lewis ; Ludlow, Aileen ; Pattison, Natalie ; Wiseman, Theresa ; Turajic, Samra ; Gore, Martin ; Larkin, James ; Husson, Olga. / An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. In: Supportive Care in Cancer. 2019 ; pp. 10.

Bibtex

@article{d0ef4b67891841acad114806002a454a,
title = "An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors",
abstract = "Purpose The immune checkpoint inhibitors (ICIs) have resulted in subgroups of patients with metastatic melanoma achievinghigh-quality durable responses. Metastatic melanoma survivors are a new population in the era of cancer survivorship. The aimofthis study was to evaluate metastatic melanoma survivors in terms of health-related quality of life (HRQoL), immune-relatedadverse events (irAEs) and exposure to immunosuppressive agents in a large single centre in the UK.Methods We defined the survivor population as patients with a diagnosis of metastatic melanoma who achieved a durableresponse to an ICI and had been followed-up for a minimum of 12 months from initiation of ICI without disease progression.HRQoL was assessed using SF-36. Electronic health records were accessed to collect data on demographics, treatments, irAEsand survival. HRQoL data was compared with two norm-based datasets.Results Eighty-four metastatic melanoma survivors were eligible and 87% (N = 73) completed the SF-36. ICI-related toxicity ofany grade occurred in 92%of patients and 43%had experienced a grade 3 or 4 toxicity. Almost half (49%) of the patients requiredsteroids for the treatment of ICI-related toxicity, whilst 14% required treatment with an immunosuppressive agent beyondsteroids.Melanoma survivors had statistically significant lower HRQoL scores with regard to physical, social and physical rolefunctioning and general health compared with the normative population. There was a trend towards inferior scores in patientswith previous exposure to ipilimumab compared with those never exposed to ipilimumab.Conclusions Our results show that metastatic melanoma survivors have potentially experienced significant ICI-related toxicityand experience significant impairments in specific HRQoL domains. Future service planning is required to meet this population{\textquoteright}sunique survivorship needs.",
keywords = "Health-related quality of life, Immune checkpoint inhibitors, Melanoma, Skin cancer",
author = "Aine O'reilly and Peta Hughes and Jasmine Mann and Zhuangming lai and {Jiat Teh}, Jiah and Kim Edmonds and Karla Lingard and Dharmisha Chauhan and Joanna Lynch and Lewis Au and Aileen Ludlow and Natalie Pattison and Theresa Wiseman and Samra Turajic and Martin Gore and James Larkin and Olga Husson",
note = "{\textcopyright} The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",
year = "2019",
month = may,
day = "14",
doi = "10.1007/s00520-019-04818-w",
language = "English",
pages = "10",
journal = "Supportive Care in Cancer",

}

RIS

TY - JOUR

T1 - An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors

AU - O'reilly, Aine

AU - Hughes, Peta

AU - Mann, Jasmine

AU - lai, Zhuangming

AU - Jiat Teh, Jiah

AU - Edmonds, Kim

AU - Lingard, Karla

AU - Chauhan, Dharmisha

AU - Lynch, Joanna

AU - Au, Lewis

AU - Ludlow, Aileen

AU - Pattison, Natalie

AU - Wiseman, Theresa

AU - Turajic, Samra

AU - Gore, Martin

AU - Larkin, James

AU - Husson, Olga

N1 - © The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PY - 2019/5/14

Y1 - 2019/5/14

N2 - Purpose The immune checkpoint inhibitors (ICIs) have resulted in subgroups of patients with metastatic melanoma achievinghigh-quality durable responses. Metastatic melanoma survivors are a new population in the era of cancer survivorship. The aimofthis study was to evaluate metastatic melanoma survivors in terms of health-related quality of life (HRQoL), immune-relatedadverse events (irAEs) and exposure to immunosuppressive agents in a large single centre in the UK.Methods We defined the survivor population as patients with a diagnosis of metastatic melanoma who achieved a durableresponse to an ICI and had been followed-up for a minimum of 12 months from initiation of ICI without disease progression.HRQoL was assessed using SF-36. Electronic health records were accessed to collect data on demographics, treatments, irAEsand survival. HRQoL data was compared with two norm-based datasets.Results Eighty-four metastatic melanoma survivors were eligible and 87% (N = 73) completed the SF-36. ICI-related toxicity ofany grade occurred in 92%of patients and 43%had experienced a grade 3 or 4 toxicity. Almost half (49%) of the patients requiredsteroids for the treatment of ICI-related toxicity, whilst 14% required treatment with an immunosuppressive agent beyondsteroids.Melanoma survivors had statistically significant lower HRQoL scores with regard to physical, social and physical rolefunctioning and general health compared with the normative population. There was a trend towards inferior scores in patientswith previous exposure to ipilimumab compared with those never exposed to ipilimumab.Conclusions Our results show that metastatic melanoma survivors have potentially experienced significant ICI-related toxicityand experience significant impairments in specific HRQoL domains. Future service planning is required to meet this population’sunique survivorship needs.

AB - Purpose The immune checkpoint inhibitors (ICIs) have resulted in subgroups of patients with metastatic melanoma achievinghigh-quality durable responses. Metastatic melanoma survivors are a new population in the era of cancer survivorship. The aimofthis study was to evaluate metastatic melanoma survivors in terms of health-related quality of life (HRQoL), immune-relatedadverse events (irAEs) and exposure to immunosuppressive agents in a large single centre in the UK.Methods We defined the survivor population as patients with a diagnosis of metastatic melanoma who achieved a durableresponse to an ICI and had been followed-up for a minimum of 12 months from initiation of ICI without disease progression.HRQoL was assessed using SF-36. Electronic health records were accessed to collect data on demographics, treatments, irAEsand survival. HRQoL data was compared with two norm-based datasets.Results Eighty-four metastatic melanoma survivors were eligible and 87% (N = 73) completed the SF-36. ICI-related toxicity ofany grade occurred in 92%of patients and 43%had experienced a grade 3 or 4 toxicity. Almost half (49%) of the patients requiredsteroids for the treatment of ICI-related toxicity, whilst 14% required treatment with an immunosuppressive agent beyondsteroids.Melanoma survivors had statistically significant lower HRQoL scores with regard to physical, social and physical rolefunctioning and general health compared with the normative population. There was a trend towards inferior scores in patientswith previous exposure to ipilimumab compared with those never exposed to ipilimumab.Conclusions Our results show that metastatic melanoma survivors have potentially experienced significant ICI-related toxicityand experience significant impairments in specific HRQoL domains. Future service planning is required to meet this population’sunique survivorship needs.

KW - Health-related quality of life

KW - Immune checkpoint inhibitors

KW - Melanoma

KW - Skin cancer

UR - http://www.scopus.com/inward/record.url?scp=85066037593&partnerID=8YFLogxK

U2 - 10.1007/s00520-019-04818-w

DO - 10.1007/s00520-019-04818-w

M3 - Article

SP - 10

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

ER -